Table 1. Density of CD68- and CD163- positive cells in the tumor field and clinical features in 100 samples of CC.
| Clinical or pathologic feature | Total number | CD68 | CD163 | ||
|---|---|---|---|---|---|
| CD68 (%) (mean ± SE) | P-value | CD163 (%) (mean ± SE) | P-value | ||
| All cases | 100 | 13.76 ± 5.63 | – | 10.08 ± 4.22 | – |
| Age at diagnosis | 0.27 | 0.35 | |||
| <45 years old | 32 | 13.21 ± 7.24 | 9.62 ± 6.35 | ||
| ≥45 years old | 68 | 14.02 ± 6.21 | 10.30 ± 5.21 | ||
| Ethnicity | 0.46 | 0.49 | |||
| Uygur | 58 | 14.13 ± 6.98 | 10.51 ± 5.94 | ||
| Han | 32 | 13.06 ± 7.18 | 9.27 ± 6.73 | ||
| Other minorities | 10 | 13.85 ± 7.23 | 10.18 ± 7.22 | ||
| Childbearing history | 0.68 | 0.54 | |||
| 0–2 times | 59 | 13.89 ± 6.01 | 10.24 ± 6.31 | ||
| ≥3 times | 41 | 13.57 ± 6.42 | 9.84 ± 6.89 | ||
| Abortion history | 0.56 | 0.38 | |||
| Yes | 61 | 13.61 ± 6.32 | 10.52 ± 5.76 | ||
| No | 39 | 13.99 ± 7.89 | 9.39 ± 6.13 | ||
| HPV status | 0.59 | 0.22 | |||
| HPV 16 | 34 | 14.18 ± 6.91 | 11.05 ± 6.63 | ||
| HVP18 | 38 | 13.71 ± 6.28 | 9.36 ± 6.09 | ||
| Other | 20 | 13.27 ± 7.67 | 9.95 ± 7.51 | ||
| Negative | 8 | 13.44 ±8.21 | 9.72 ± 7.89 | ||
| Tumor size | 0.22 | 0.64 | |||
| ≤4 cm | 47 | 13.41 ± 6.97 | 9.95 ± 6.28 | ||
| >4 cm | 53 | 14.07 ± 6.45 | 10.19 ± 5.35 | ||
| Differentiation | 0.18 | 0.21 | |||
| Low | 49 | 13.26 ± 7.02 | 10.09 ± 5.42 | ||
| Middle/High | 51 | 14.24 ± 6.82 | 10.07 ± 5.29 | ||
| FIGO stage | 0.19 | 0.04 | |||
| IA ∼ IB | 52 | 13.25 ± 6.98 | 9.07 ± 6.17 | ||
| ≥ IIA | 48 | 14.31 ± 7.34 | 11.17 ± 6.42 | ||
| Lymph node metastases | 0.03 | 0.04 | |||
| Yes | 32 | 15.92 ± 8.24 | 11.23 ± 7.26 | ||
| No | 68 | 12.74 ± 6.99 | 9.54 ± 6.14 | ||
Abbreviations: SE, Standard error.
Note: Independent-samples t-test or ANOVA test was used; Kruskal–Wallis test (K-W) was used when unequal variances. P<0.05 was considered significant.